M&As this week: Smith & Nephew, Nordic Capital Fund IX, Biocoat

25 January 2019 (Last Updated January 25th, 2019 09:39)

Smith & Nephew has acquired Ceterix® Orthopaedics for $50m, as part of its strategy to invest in innovative technologies that meet unmet clinical needs.

Smith & Nephew has acquired Ceterix® Orthopaedics for $50m as part of its strategy to invest in innovative technologies for unmet clinical needs.

The company has also agreed to pay up to $55m over the next five years, based on financial performance.

Based in the UK, Smith & Nephew company is engaged in manufacturing medical equipment. Ceterix® Orthopaedics is a US-based developer of surgical tools for arthroscopic procedures and the NovoStitch® Pro Meniscal Repair System.

Nordic Capital Fund IX has reached an agreement with Altor Fund III (Altor) to acquire a majority holding in Orchid Orthopedic Solutions (Orchid).

Financial terms of the deal have not been disclosed.

Based in the US, Orchid designs and manufactures implants for the orthopaedic market, while Nordic Capital, based in Europe, is a private equity investor with successful healthcare investments in North America.

1315 Capital has acquired Biocoat as part of its growth-oriented strategy to enter the biomaterial coatings market for medical devices.

“The acquisition is intended to increase 1315 Capital’s business offering by making use of Biocoat’s differentiated technology.”

The acquisition is intended to increase 1315 Capital’s business offering by making use of Biocoat’s differentiated technology.

1315 Capital is engaged in providing expansion and growth capital to commercial-stage healthcare services, medical technology, and speciality pharmaceutical companies. Biocoat is involved in the development and licensing of biomaterial coatings for medical devices. Both companies are based in the US.

Abbott has acquired Cephea Valve Technologies by exercising its previously held option secured in 2015.

The acquisition of Cephea is part of Abbott’s strategy to develop comprehensive treatments for people with mitral valve disease and will help the company in maintaining its position in structural heart therapies.

Abbott is a global healthcare company engaged in conducting innovative research and manufactures products for human health. Cephea Valve Technologies is a privately held medical device company, which develops less-invasive heart valve replacement technology for people with mitral valve disease. Both companies are based in the US.